MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
ROCKVILLE, Md., Oct. 11, 2024 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing […]
Alignment Healthcare Continues to Deliver High-Quality Medicare Advantage Plans, 4 Stars or Greater for 98% of Members in 2025
ORANGE, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) — Alignment Healthcare, Inc. (NASDAQ: ALHC) announced today that 98% of its Alignment […]
Paltalk Holdings Announces Judge Enters Final Judgment in Connection With Cisco Jury Verdict
JERICHO, N.Y. , Oct. 11, 2024 (GLOBE NEWSWIRE) — Paltalk, Inc. (“Paltalk,” the “Company,” “we,” our,” or “us”) (NASDAQ: PALT), […]
Par Pacific Announces Third Quarter 2024 Earnings Release and Conference Call Schedule
HOUSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) — Par Pacific Holdings, Inc. (NYSE: PARR) (“Par Pacific”) today announced that it will […]
Global Uranium Corp. Prepares to Commence Ground-Based Radiometric Survey on Wyoming Projects
CALGARY, Alberta, Oct. 11, 2024 (GLOBE NEWSWIRE) — Global Uranium Corp. (CSE: GURN | OTCQB: GURFF | FRA: Q3J) (the […]
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
MELBOURNE, Australia and SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the […]
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) — Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing […]
Better Choice Company to Expand into Veterinary Medicine in 2025 Following the Acquisition of SRx Health
TAMPA, Fla., Oct. 11, 2024 (GLOBE NEWSWIRE) — Better Choice Company (NYSE: BTTR) (“Better Choice” or “the Company”), a pet […]
AGBA ADVANCES TOWARD COMPLETION OF THE TRILLER MERGER
AGBA Group Holding Limited (Nasdaq: AGBA) (“AGBA” or the “Company”) and Triller Corp. (“Triller”), today announced that their merger is […]
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
– Treatment with denifanstat achieved statistically significant and clinically meaningful improvements in disease activity, MASH resolution and fibrosis –– Results […]
